185 related articles for article (PubMed ID: 38792468)
21. A multicenter, open-label extension study of velaglucerase alfa in Japanese patients with Gaucher disease: Results after a cumulative treatment period of 24months.
Ida H; Tanaka A; Matsubayashi T; Murayama K; Hongo T; Lee HM; Mellgard B
Blood Cells Mol Dis; 2016 Jul; 59():140-7. PubMed ID: 27241455
[TBL] [Abstract][Full Text] [Related]
22. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.
Ben Turkia H; Gonzalez DE; Barton NW; Zimran A; Kabra M; Lukina EA; Giraldo P; Kisinovsky I; Bavdekar A; Ben Dridi MF; Gupta N; Kishnani PS; Sureshkumar EK; Wang N; Crombez E; Bhirangi K; Mehta A
Am J Hematol; 2013 Mar; 88(3):179-84. PubMed ID: 23400823
[TBL] [Abstract][Full Text] [Related]
23. Velaglucerase alfa: a new option for Gaucher disease treatment.
Zimran A
Drugs Today (Barc); 2011 Jul; 47(7):515-29. PubMed ID: 22013559
[TBL] [Abstract][Full Text] [Related]
24. A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability.
Pastores GM; Rosenbloom B; Weinreb N; Goker-Alpan O; Grabowski G; Cohn GM; Zahrieh D
Genet Med; 2014 May; 16(5):359-66. PubMed ID: 24263462
[TBL] [Abstract][Full Text] [Related]
25. Spotlight on taliglucerase alfa in the treatment of pediatric patients with type 1 Gaucher disease.
Gupta P; Pastores GM
Pediatric Health Med Ther; 2017; 8():73-81. PubMed ID: 29388611
[TBL] [Abstract][Full Text] [Related]
26. Effects of switching from a reduced dose imiglucerase to velaglucerase in type 1 Gaucher disease: clinical and biochemical outcomes.
van Dussen L; Cox TM; Hendriks EJ; Morris E; Akkerman EM; Maas M; Groener JE; Aerts JM; Deegan PB; Hollak CE
Haematologica; 2012 Dec; 97(12):1850-4. PubMed ID: 22773601
[TBL] [Abstract][Full Text] [Related]
27. Bone marrow involvement in Gaucher disease at MRI : what long-term evolution can we expect under enzyme replacement therapy?
Fedida B; Touraine S; Stirnemann J; Belmatoug N; Laredo JD; Petrover D
Eur Radiol; 2015 Oct; 25(10):2969-75. PubMed ID: 25875285
[TBL] [Abstract][Full Text] [Related]
28. Significant and continuous improvement in bone mineral density among type 1 Gaucher disease patients treated with velaglucerase alfa: 69-month experience, including dose reduction.
Elstein D; Foldes AJ; Zahrieh D; Cohn GM; Djordjevic M; Brutaru C; Zimran A
Blood Cells Mol Dis; 2011 Jun; 47(1):56-61. PubMed ID: 21536468
[TBL] [Abstract][Full Text] [Related]
29. Development of anti-velaglucerase alfa antibodies in clinical trial-treated patients with Gaucher disease.
Pastores GM; Turkia HB; Gonzalez DE; Ida H; Tantawy AA; Qin Y; Qiu Y; Dinh Q; Zimran A
Blood Cells Mol Dis; 2016 Jul; 59():37-43. PubMed ID: 27282565
[TBL] [Abstract][Full Text] [Related]
30. Retrospective Analysis of Whole-Body Magnetic Resonance Imaging of Bone Manifestations in Long-Term Treated Patients with Gaucher Disease Type 1.
Lollert A; Laudemann K; Mengel E; Hoffmann C; Moos L; Reinke J; Brixius-Huth M; Hennermann JB; Düber C; Staatz G
Klin Padiatr; 2019 Mar; 231(2):52-59. PubMed ID: 30481833
[TBL] [Abstract][Full Text] [Related]
31. Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naïve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials.
Elstein D; Mellgard B; Dinh Q; Lan L; Qiu Y; Cozma C; Eichler S; Böttcher T; Zimran A
Mol Genet Metab; 2017 Sep; 122(1-2):113-120. PubMed ID: 28851512
[TBL] [Abstract][Full Text] [Related]
32. [Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI].
Tóth J; Szücs FZ; Benkö K; Maródi L
Orv Hetil; 2003 Apr; 144(16):749-55. PubMed ID: 12778625
[TBL] [Abstract][Full Text] [Related]
33. Bone marrow burden score is not useful as a follow-up parameter in stable patients with type 1 Gaucher disease after 5 years of treatment.
Paskulin LD; Starosta RT; Bertholdo D; Vairo FP; Vedolin L; Schwartz IVD
Blood Cells Mol Dis; 2021 Sep; 90():102591. PubMed ID: 34242856
[TBL] [Abstract][Full Text] [Related]
34. Skeletal Manifestations, Bone Pain, and BMD Changes in Albanian Type 1 Gaucher Patients Treated with Taliglucerase Alfa.
Velmishi V; Troja E; Tanka M; Bali D; Dervishi E; Tako A; Kollcaku L; Cullufi P
J Osteoporos; 2023; 2023():3254533. PubMed ID: 38090017
[TBL] [Abstract][Full Text] [Related]
35. Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: early Access Program results from Jerusalem.
Elstein D; Altarescu G; Maayan H; Phillips M; Abrahamov A; Hadas-Halpern I; Tiomkin M; Zimran A
Blood Cells Mol Dis; 2012 Jan; 48(1):45-50. PubMed ID: 22047948
[TBL] [Abstract][Full Text] [Related]
36. Treatment-naïve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4years in phase 3 trials.
Zimran A; Elstein D; Gonzalez DE; Lukina EA; Qin Y; Dinh Q; Turkia HB
Blood Cells Mol Dis; 2018 Feb; 68():153-159. PubMed ID: 27839979
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of Bone Marrow Infiltration in Non-Neuropathic Gaucher Disease Patients with Use of Whole-Body MRI--A Retrospective Data Analysis.
Laudemann K; Moos L; Mengel KE; Lollert A; Reinke J; Brixius-Huth M; Wagner D; Düber C; Staatz G
Rofo; 2015 Dec; 187(12):1093-8. PubMed ID: 26200566
[TBL] [Abstract][Full Text] [Related]
38. An evidence-based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher disease.
Hollak CE
Core Evid; 2012; 7():15-20. PubMed ID: 22654679
[TBL] [Abstract][Full Text] [Related]
39. Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience.
Zimran A; Altarescu G; Philips M; Attias D; Jmoudiak M; Deeb M; Wang N; Bhirangi K; Cohn GM; Elstein D
Blood; 2010 Jun; 115(23):4651-6. PubMed ID: 20299511
[TBL] [Abstract][Full Text] [Related]
40. Home infusion of intravenous velaglucerase alfa: Experience from pooled clinical studies in 104 patients with type 1 Gaucher disease.
Elstein D; Burrow TA; Charrow J; Giraldo P; Mehta A; Pastores GM; Lee HM; Mellgard B; Zimran A
Mol Genet Metab; 2017; 120(1-2):111-115. PubMed ID: 27614581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
